Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C30H32F6N4O |
| Molecular Weight | 578.5917 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C2=C(C=C(N=C2)N3CCN(C)CC3)C4=C(C)C=CC=C4
InChI
InChIKey=WAXQNWCZJDTGBU-UHFFFAOYSA-N
InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205718s002lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792159Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=16332435; http://www.ncbi.nlm.nih.gov/pubmed/?term=24631949
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205718s002lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792159
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=16332435; http://www.ncbi.nlm.nih.gov/pubmed/?term=24631949
Fosnetupitant is a prodrug form of netupitant. Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Upon intravenous administration, fosnetupitant is converted by phosphatases to its active form. It competitively binds to and blocks the activity of NK-1 receptors in the central nervous system, by inhibiting binding of substance P (SP) to NK-1 receptors. This prevents delayed emesis, which is associated with SP secretion. AKYNZEO® is a combination of palonosetron, a serotonin-3 receptor antagonist, and netupitant (capsules for oral use) or fosnetupitant (injections for intravenous use). AKYNZEO® for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=22732666https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210493Orig1s000OtherR.pdf
Curator's Comment: Studies in rodents suggest that Netupitant behaves as a brain penetrant, orally active
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=16332435https://adisinsight.springer.com/drugs/800047603
Curator's Comment: # F. Hoffmann-La Roche Ltd
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL249 |
0.95 nM [Ki] | ||
Target ID: P25103 Gene ID: 6869.0 Gene Symbol: TACR1 Target Organism: Homo sapiens (Human) |
0.95 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | AKYNZEO Approved UseAKYNZEO for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Launch Date2018 |
|||
| Preventing | Akynzeo Approved UseTo treat nausea and vomiting in patients undergoing cancer chemotherapy Launch Date2014 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
434 ng/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
NETUPITANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14401 ng × h/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
NETUPITANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
96 h |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
NETUPITANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.5% |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
NETUPITANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
Other AEs: Palpitations, Constipation... Other AEs: Palpitations (2%) Sources: Constipation (4.1%) Pain in extremity (2%) Dizziness (2%) Headache (10.2%) Somnolence (2%) Anxiety (2%) Euphoric mood (2%) |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
Disc. AE: Neutropenia, Neoplasm progression... AEs leading to discontinuation/dose reduction: Neutropenia (0.5%) Sources: Neoplasm progression (0.5%) Neoplasm malignant (0.4%) Febrile neutropenia (0.2%) Leukopenia (0.2%) Thrombocytopenia (0.1%) Peritonitis (0.1%) Troponin increased (0.1%) Stomatitis (0.2%) ALT increased (0.2%) Platelet count decreased (0.2%) Angina pectoris (0.1%) Myocardial ischaemia (0.1%) Creatinine renal clearance decreased (0.1%) |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
Other AEs: Febrile neutropenia, Neutropenia... Other AEs: Febrile neutropenia (1.5%) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130Neutropenia (1%) Vomiting (0.6%) Anaemia (0.5%) Leukopenia (0.3%) Pneumonia (0.4%) Urinary tract infection (0.3%) Pulmonary embolism (0.2%) Cardiopulmonary failure (0.3%) Stomatitis (0.3%) Asthenia (0.2%) Neoplasm malignant (0.2%) Nausea (0.1%) Peritonitis (0.1%) Renal failure (0.1%) Abdominal pain (0.2%) Diarrhoea (0.2%) Multi-organ failure (0.2%) Pyrexia (0.2%) Femur fracture (0.2%) Neoplasm progression (0.2%) Metrorrhagia (0.2%) Haemoptysis (0.2%) Thrombocytopenia (0.1%) Electrolyte imbalance (0.1%) Convulsion (0.1%) Deep vein thrombosis (0.1%) |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
Other AEs: ALT increased, AST increased... Other AEs: ALT increased (grade 3, 1.3%) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135AST increased (grade 3, 0.8%) AST increased (grade 4, 0.1%) Alkaline phosphatase increased (grade 3, 0.4%) Hyperglycemia (grade 3, 7.8%) Hyperglycemia (grade 4, 0.6%) Hypokalemia (grade 3, 1.4%) Hypokalemia (grade 4, 0.4%) Hyponatremia (grade 3, 4.9%) Hyponatremia (grade 4, 0.6%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headache | 10.2% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Anxiety | 2% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Dizziness | 2% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Euphoric mood | 2% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Pain in extremity | 2% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Palpitations | 2% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Somnolence | 2% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Constipation | 4.1% | 600 mg 1 times / day single, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: single Dose: 600 mg, 1 times / day Co-administed with:: palonosetron(1.5 mg; single dose) Sources: |
healthy, mean age 32.8 years n = 49 Health Status: healthy Age Group: mean age 32.8 years Sex: M+F Population Size: 49 Sources: |
| Angina pectoris | 0.1% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Creatinine renal clearance decreased | 0.1% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Myocardial ischaemia | 0.1% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Peritonitis | 0.1% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Thrombocytopenia | 0.1% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Troponin increased | 0.1% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| ALT increased | 0.2% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Febrile neutropenia | 0.2% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Leukopenia | 0.2% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Platelet count decreased | 0.2% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Stomatitis | 0.2% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Neoplasm malignant | 0.4% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Neoplasm progression | 0.5% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Neutropenia | 0.5% Disc. AE |
300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: |
| Convulsion | 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Deep vein thrombosis | 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Electrolyte imbalance | 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Nausea | 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Peritonitis | 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Renal failure | 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Thrombocytopenia | 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Abdominal pain | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Asthenia | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Diarrhoea | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Femur fracture | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Haemoptysis | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Metrorrhagia | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Multi-organ failure | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Neoplasm malignant | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Neoplasm progression | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Pulmonary embolism | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Pyrexia | 0.2% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Cardiopulmonary failure | 0.3% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Leukopenia | 0.3% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Stomatitis | 0.3% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Urinary tract infection | 0.3% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Pneumonia | 0.4% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Anaemia | 0.5% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Vomiting | 0.6% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Neutropenia | 1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Febrile neutropenia | 1.5% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130 |
| Alkaline phosphatase increased | grade 3, 0.4% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| AST increased | grade 3, 0.8% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| ALT increased | grade 3, 1.3% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| Hypokalemia | grade 3, 1.4% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| Hyponatremia | grade 3, 4.9% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| Hyperglycemia | grade 3, 7.8% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| AST increased | grade 4, 0.1% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| Hypokalemia | grade 4, 0.4% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| Hyperglycemia | grade 4, 0.6% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
| Hyponatremia | grade 4, 0.6% | 300 mg 1 times / 5 weeks multiple, oral Recommended Dose: 300 mg, 1 times / 5 weeks Route: oral Route: multiple Dose: 300 mg, 1 times / 5 weeks Co-administed with:: palonosetron(0.5 mg; prior to the start of chemotherapy cycle) Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
unhealthy, median age 55 years n = 1033 Health Status: unhealthy Condition: cancer Age Group: median age 55 years Sex: M+F Population Size: 1033 Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| weak [IC50 22.6 uM] | ||||
| weak [IC50 23.73 uM] | ||||
| weak [IC50 26.41 uM] | ||||
| weak [IC50 33.26 uM] | ||||
| weak [IC50 38.84 uM] | ||||
| weak [IC50 39.04 uM] | ||||
| weak [IC50 39.39 uM] | ||||
| weak [IC50 57.45 uM] | ||||
| weak [IC50 6 uM] | ||||
| weak [IC50 8.6 uM] | ||||
| weak | ||||
| weak | ||||
| yes [IC50 1.2 uM] | ||||
| yes [IC50 19 uM] | ||||
| yes [IC50 22.3 uM] | ||||
| yes [IC50 22.6 uM] | ||||
| yes [IC50 33.38 uM] | ||||
| yes [IC50 4.74 uM] | ||||
| yes [IC50 4.89 uM] | ||||
| yes [IC50 4.95 uM] | ||||
| yes [IC50 50.4 uM] | ||||
| yes [IC50 7.4 uM] | ||||
| yes [IC50 7.9 uM] | ||||
| yes [IC50 8 uM] | ||||
| yes [IC50 8.54 uM] | ||||
| yes [Ki 1.1 uM] | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | yes (co-administration study) Comment: Administration of the CYP3A4 inhibitor ketoconazole with netupitant/palonosetron FDC increased the exposure of netupitant and resulted in an AUC0-tz of 1.8 fold, AUC0-’ of 2.4 fold, and Cmax of 1.3 fold when compared to the administration of netupitant/palonosetron FDC alone. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000ClinPharmR.pdf#page=73 Page: 73.0 |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sample Use Guides
One AKYNZEO (netupitant and palonosetron) capsule administered approximately 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy on day 1 and 8 mg orally once daily on days 2 to 4 (for highly emetogenic chemotherapy, including cisplatin based chemotherapy) or on day 1 with not necessary administration of dexamethasone on days 2 to 4 (for anthracyclines and cyclophosphamide based chemotherapy and chemotherapy not considered highly emetogenic)
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
AKYNZEO (AUTHORIZED: NAUSEA)
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
||
|
NDF-RT |
N0000175786
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
||
|
NCI_THESAURUS |
C267
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000156565
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
6451149
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
RR-56
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
8409
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
7732P08TIR
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
7732P08TIR
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL206253
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
85155
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
N0000190113
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | Breast Cancer Resistance Protein Inhibitors [MoA] | ||
|
290297-26-6
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
4898
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
N0000182141
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | Cytochrome P450 3A4 Inhibitors [MoA] | ||
|
N0000185503
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | P-Glycoprotein Inhibitors [MoA] | ||
|
SUB130488
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
Netupitant
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
DTXSID50183271
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
5742
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
DB09048
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
C96745
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
C508854
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | |||
|
1552337
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY | RxNorm | ||
|
m11791
Created by
admin on Sat Dec 16 15:53:34 GMT 2023 , Edited by admin on Sat Dec 16 15:53:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
